US equities |
SPCX $168.76 ▲+6.17% NVDA $237.71 ▲+1.61% MU $1,064.88 ▼-0.93% TSLA $380.75 ▲+2.74% MSFT $525.04 ▲+1.45% SNDK $1,715.45 ▼-0.26% INTC $116.88 ▼-2.05% META $744.68 ▲+2.28%
FinancialContent

Aytu BioPharma, Inc. - Common Stock (NQ:AYTU)

2.100 +0.030 (+1.45%)
Delayed Quote Updated: 1:37 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023 ↗
 
Via Benzinga
News headline image
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
News headline image
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Via ACCESSWIRE
News headline image
Aytu BioPharma: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
A Preview Of Aytu BioPharma's Earnings ↗
 
Via Benzinga
News headline image
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
News headline image
Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying ↗
The Dow Jones closed higher by over 400 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Via ACCESSWIRE
News headline image
AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates ↗
AYTU stock earnings show Aytu Biopharma missing earnings per share and revenue estimates for the fiscal third quarter. 
Via InvestorPlace
News headline image
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
Via ACCESSWIRE
News headline image
Aytu BioPharma's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Via ACCESSWIRE
News headline image
Earnings Preview For Aytu BioPharma ↗
 
Via Benzinga
News headline image
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Via ACCESSWIRE
News headline image
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket ↗
Gainers Leju Holdings Limited (NYSE: LEJU) gained 103.7% to $7.25 in pre-market trading after jumping around 97% on Monday . 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! 
Via InvestorPlace
News headline image
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
Via ACCESSWIRE
News headline image
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
Via ACCESSWIRE
News headline image
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
Via ACCESSWIRE
News headline image
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Via ACCESSWIRE
News headline image
Earnings Scheduled For February 14, 2023 ↗
Companies Reporting Before The Bell • WESCO International (NYSE:WCC) is projected to report quarterly earnings at $3.79 per share on revenue of $5.37 billion. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >